Company intelligence / Profile preview

Tian-I

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Tian-I Therapeutics is a biotechnology company specializing in the development of circular RNA (circRNA) therapies. The company leverages its proprietary platform to design and produce circRNA molecules with enhanced stability and translation efficiency compared to linear mRNA. Their pipeline focuses on protein replacement therapies for rare diseases, cancer immunotherapies, and next-generation vaccines. Tian-I aims to overcome the limitations of traditional mRNA technologies by utilizing the unique structural properties of circular RNA for prolonged therapeutic effects.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: RNA therapyVaccinecircRNA
Industry: Biotech

Partnerships

Peking University

Beyond the preview

Go deeper on Tian-I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tian-I.

Explore the full profile